Cleveland HeartLab, Inc.

Independent biotechnology consulting. All topics related to drug discovery in the therapeutic areas of oncology, cardiovascular, angiogenesis, and inflammation. Expertise in additional areas of Ophthalmology (diabetic retinopathy, macular degeneration) Assistance in research planning and protocols, contracts with academic and commercial laboratories, editing and preparation of manuscripts, grant applications, research strategy, protocols for cell based assays, pharmacodynamic assays, and biomarker studies.

Invivotek LLC, a member of Genesis Biotechnology Group® (GBG) is a global pre-clinical contract research organization (CRO) specializing in small animal studies for drug discovery and early optimization. Invivotek's facility was opened in 2012 and our first commercial project launched in 2013.

Invivotek offers both custom and standard pre-clinical services for drug discovery and development programs for our clients. Invivotek’s portfolio includes animal models and bioassays designed to support in vivo testing of compounds related to Immunology and Inflammation, Oncology, Metabolic, and Cardiovascular diseases. Invivotek’s in vivo testing capabilities are supported by biochemical and molecular biology techniques as well as functional assays with primary cell cultures established from various mouse tissues under disease model and normal conditions. These assays provide tools to study the mechanism of action of various test therapeutics or potential target genes and to explore drug efficacy biomarkers. The collective experience across multiple therapeutic areas in conjunction with the business and project management skills of the team working in a state-of-the-art animal facility, position Invivotek as a leading provider of preclinical in vivo services.

Our company is recognized for excellence in providing ISO 9001monoclonal and polyclonal antibodies, antigens, enzymes, and purified proteins to the research and medical diagnostic marketplace. Nearly all of our products are validated for usage in quantitative sandwich immunoassay and qualitative rapid testing.

We offer immunological reagents worldwide for diagnostics & research in the following disciplines:

Infectious Diseases (60)
Neuroscience (45)
Inflammation (43)
Veterinary (41)
Cardiac Markers (36)
Gangliosides & Globosides (33)
Tumor Markers (26)
Hormones (22)
Microbial & Plant Toxins (21)
Metabolic Syndrome (15)
Blood Coagulation and Anemia (12)
Biodefense (10)
Kidney Diseases (4)
Fertility and Pregnancy (2)


We are happy to inform you that Advanced ImmunoChemical is now offering a set of antibodies produced In vitro. In addition, some of our current antibodies are now available both as In vivo- and In vitro-produced products.

Monoclonal antibodies and mammalian antigens for detecting infectious diseases, cardiac biomarkers, and hormones.

Broad selection antibodies and inactivated viral antigens to detect Influenza A and B in clinical samples.
Monoclonal antibodies for the detection of biological threats and dangerous pathogens.

Biomarkers for cardiovascular disease prevention, risk assessment, and diagnostics.

Customers Include: Princeton University, Duke University School of Medicine, Columbia University Medical Center, CDC, National Institutes of Health, Naval Health Research Center, Los Alamos National Laboratory, US Army Medical Research Institute of Infectious Diseases, Sandia National Laboratories, Stanfored Medicine, NIST, NIMH, Harvard Medical School, Yale University School of Medicine, John Hopkins School of Medicine, Lawrence Livermore National Laboratory, and many more!

Advanced ImmunoChemical is a WBENC-certified woman-owned small business, since 1986.

Kinexus Bioinformatics Corporation maps and monitors the molecular communications networks of living cells for biomedical research into the diagnosis, prognosis and treatment of human diseases. In particular, the company tracks enzymes called protein kinases that control other proteins by carrying out their phosphorylation at regulatory sites known as phosphosites. Phosphosites act as on/off switches for proteins. Their malfunction has been linked to more than 400 human diseases, including cancer, cardiovascular disease, diabetes and inflammation.

Currently, Kinexus measures the presence and activation states of over 650 different protein kinases and other regulatory proteins and many of their phosphosites in cell and tissue specimens through our integrated platform of cell culture, protein microarray, immunoblotting, mass spectrometry and immunohistochemistry services.

These innovative proprietary services utilize unique and stringent screening methods to facilitate the discovery and validation of biomarkers, drug targets and the rapid exclusion of inappropriate drug leads in the early stages of the drug discovery process. This is further augmented by a suite of open source, online bioinformatics services that are offered by Kinexus. Our bioinformatics studies are helping us to create new tools for biomedical research that include enzymes, antibodies and peptides.

For over 12 years, Kinexus has provided our unique services to over 1600 laboratories in 35 countries.

Multispan, Inc. is a premier assay screening technology provider targeting GPCRs, kinases and beyond using endogenously expressed targets in primary cells and recombinant stable cell lines. It has created the industry’s largest, highly characterized, highest quality GPCR-expressing stable cell lines and assays based on cell signaling and phenotypic biology. Multispan offers integrated high quality solutions in assay development, HTS and SAR lead optimization screening support to shorten time to IND and discover better medicine in cardiovascular, metabolic, CNS, inflammation, immunology and oncology diseases. Multispan’s high standard of quality and integrity has earned successful long-term collaborations with a wide range of leading pharmaceutical and biotech companies globally.